Skip to main content
. 2012 Nov 15;8(2):219–224. doi: 10.2215/CJN.03680412

Table 1.

Patient characteristics

Characteristic Intravenous CYP MEPEX
Number of patients 41 37
Age (yr), median (range) 62 (19–98) 64 (28–80)
ANCA type, n
 MPO 20 19
 PR3 19 12
 ANCA negative 1 6
 MPO and PR3 1
Pulmonary hemorrhage, n (%) 13 (32) 7 (19)
Extrarenal involvement, n (%) 18 (44) 24 (65)

CYP, cyclophosphamide; MPO, myeloperoxidase; PR3, proteinase 3; MEPEX, methylprednisolone versus plasma exchange (oral cyclophosphamide cohort).